Lexaria Bioscience Corp. (LEXX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Lexaria Bioscience Corp. (LEXX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.93

-0.13 (-6.31%)

At close: Jan 14, 2025, 3:59 PM

1.86

-3.47%

Pre-market Jan 15, 2025, 06:19 AM EST

undefined% (undefined)

Bid	1.9
Market Cap	33.63M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.5
PE Ratio (ttm)	-3.85
Forward PE	n/a
Analyst	Buy

Ask	1.98
Volume	2,299,392
Avg. Volume (20D)	154,909
Open	2.01
Previous Close	2.06
Day's Range	1.62 - 2.08
52-Week Range	1.36 - 6.85
Beta	undefined

About LEXX

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 12, 2021

Employees 5

Stock Exchange NASDAQ

Ticker Symbol LEXX

Website https://www.lexariabioscience.com

Analyst Forecast

According to 2 analyst ratings, the average rating for LEXX stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 470.89% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 day ago · Source New

-6.31%

Lexaria Bioscience shares are trading lower. The c... Unlock content with Pro Subscription

8 months ago · Source

+0.32%

Lexaria Bioscience shares are trading higher after the company announced it has began dosing in its GLP-1 animal study.

News

3 weeks ago · https://thefly.com

Lexaria Bioscience's Phase 1b study starts patient dosing, says H.C. Wainwright

H.C. Wainwright reiterates a Buy rating and $10 price target on Lexaria Bioscience shares after the company announced that the Phase 1b 12-week chronic study in Australia has started patient dosing as...